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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYNeural stem cell (NSC) transplantation is a promising strategy for delivering therapeutic proteins in the brain. We evaluated a complete
process of ex vivo gene therapy using human induced pluripotent stem cell (iPSC)-derivedNSC transplants in a well-characterizedmouse
model of a human lysosomal storage disease, Sly disease. Human Sly disease fibroblastswere reprogrammed into iPSCs, differentiated into
a stable and expandable population of NSCs, genetically corrected with a transposon vector, and assessed for engraftment in NOD/SCID
mice. Following neonatal intraventricular transplantation, the NSCs engraft along the rostrocaudal axis of the CNS primarily within
white matter tracts and survive for at least 4 months. Genetically corrected iPSC-NSCs transplanted post-symptomatically into the stria-
tum of adult Sly diseasemice reversed neuropathology in a zone surrounding the grafts, while control mock-corrected grafts did not. The
results demonstrate the potential for ex vivo gene therapy in the brain using human NSCs from autologous, non-neural tissues.INTRODUCTION
Neural stem cells (NSCs), the self-renewing precursors of
neurons and glia within the developing and adult brain,
have the potential to serve as delivery vehicles for thera-
peutics in the CNS. Transplanted NSCs have been shown
to migrate, engraft long term, and secrete beneficial levels
of exogenous protein (Aboody et al., 2011; Snyder et al.,
1995). There are numerous potential sources of transplant-
able NSCs, and the development of efficacious therapies
will depend on improved methods for their derivation
and propagation (Conti and Cattaneo, 2010).
Potential sources of NSCs include cell lines, pluripotent
stem cell-derived NSCs, and primary NSCs harvested
from fetal or adult animals. Some immortalized NSC lines
can engraft and migrate extensively (Snyder et al., 1995),
but they may have unstable genomes or pose a risk of
tumorigenesis (Koso et al., 2012; Mi et al., 2005; Snyder
et al., 1995). Protocols for the differentiation of human em-
bryonic stem cells (ESCs) allow for potentially unlimited
expansion of transplantable NSCs, but ESC-derived NSCs
are generally incompatible with the host immune system
(Koch et al., 2009). Primary NSCs derived from the patient
would circumvent immune rejection, but are difficult to
obtain and have a relatively limited capacity for expansion
and engraftment (Chaubey andWolfe, 2013; Walton et al.,
2008; Wright et al., 2006). A compelling potential solution
to this problem involves the use of patient-specific induced
pluripotent stem cells (iPSCs), which offer a readily obtain-
able source of immunologically compatible cells that
possess the broad expansion and engraftment potential
of ESCs (Guha et al., 2013). The combination of iPSC tech-Stemnology, ESC to NSC differentiation methods, and ex vivo
gene therapy offers a promising template for treating a
wide range of CNS disorders.
Lysosomal storage diseases (LSDs), which are among the
most prevalent monogenetic disorders affecting the brain,
may be particularly amenable to this strategy (Meikle et al.,
1999). Most often the result of a nonfunctional lysosomal
hydrolase, LSDs result in the pathological accumulation
of various proteins, lipids, and sugars within the cell.
Neuropathology is a significant component of most LSDs,
and neurons are particularly susceptible to the accumula-
tion of waste products and associated inflammatory pro-
cesses (Platt et al., 2012). Intravenous enzyme replacement
therapy (ERT) is ineffectual in the CNS due to the imperme-
ability of the blood-brain barrier (Augustine and Mink,
2013), and while intrathecal ERT may be efficacious, it re-
quires regular infusions (Kakkis et al., 2004). NSC-based
gene therapy is a potential approach to overcome these
obstacles. Donor NSCs can secrete therapeutic levels of
lysosomal enzymes, which traffic to host cell lysosomes
via themannose-6-phosphate pathway in a process known
as cross-correction (Simonato et al., 2013; Snyder and
Wolfe, 1996).
Sly disease (MPS VII) is a prototypical LSD with which to
test the efficacy of NSC transplantation due to the availabil-
ity of cognate animal models and sensitive enzyme assays
(Wolfe and Sands, 1996). Here, we utilize the NOD/SCID/
MPSVIImodel (Hofling et al., 2003) to demonstrate an inte-
grated process bywhich patient somatic cells can be reprog-
rammed, differentiated into a relevant cell type (NSCs),
genetically corrected, and transplanted to yield a therapeu-
tic effect in a mouse homolog of the human disease.Cell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authors 835
Figure 1. Generation of iPSCs from an MPS VII Patient
Fibroblasts from a female patient with MPS VII (GM02784) were transduced with retroviral vectors expressing the reprogramming factors
OCT4, SOX2, KLF4, and c-MYC. A putative iPSC line was isolated and expanded under serum-free conditions on a feeder layer of mouse
embryonic fibroblasts.
(A–D) MPS VII iPSC colonies, seen in the phase contrast image (A), expressed markers of pluripotency (B–D).
(E–K) After injection into immunodeficient mice, MPS VII iPSCs formed teratomas (E) that differentiated into the three primary germ layers
as shown by H&E-stained sections (E–H) and germ layer-specific marker expression (I–K). a-FP, a-fetoprotein; SMA, smooth muscle actin;
Tuj1, bIII-tubulin.
Scale bars represent 200 mm (except in E).RESULTS
Generation and Characterization of MPS VII iPSCs
Frozen dermal fibroblasts from a patient with MPS VII
(GM02784; Coriell Institute) were thawed, expanded, and
transduced with vesicular stomatitis virus G protein
(VSV-G) pseudotyped retroviral vectors expressing OCT4,
SOX2, KLF-4, and c-MYC to initiate reprogramming.
Despite the fact that these fibroblasts had been frozen
for 30 years, colonies of ESC-like cells emerged alongside
aggregates of partially reprogrammed cells, consistent with
previous reports (Chan et al., 2009). One line was selected
for further characterization.
To confirm the pluripotency of MPS VII iPSCs, we per-
formed standard in vitro and in vivo assays. The putative
MPS VII-iPSC line displayed typical ESC/iPSC-like colony
morphology (Figure 1A) and expressed multiple markers
of pluripotency, including SSEA4, Tra-1-60, and Tra-1-81
(Figures 1B–1D). Cells injected into immunodeficient
mice formed teratomas containing the three primary
germ layers. H&E-stained teratoma sections revealed struc-
tures typical of endoderm, ectoderm, and mesoderm (Fig-
ures 1E–1H), and immunostained teratoma sections were836 Stem Cell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authopositive for markers of each lineage (Figures 1I–1K). iPSCs
were passaged >40 times with no change in morphology
or pluripotency marker expression.
Differentiation of MPS VII iPSC-NSCs
MPS VII and control iPSCs were passaged at least 20 times
before being subjected to an adapted NSC differentiation
protocol (Koch et al., 2009) (Figure 2). After iPSCs were
removed from the mouse embryonic fibroblast (MEF)
feeder layer and grown in suspension culture containing
fetal bovine serum (FBS), they formed large spherical
aggregates. These embryoid bodies were plated and grown
in a minimal neural induction medium. A variety of cell
types grew outward from the plated aggregates, including
many with neurite-like extensions. After approximately
2 weeks, neural tube-like structures began to form on
some cell aggregates, consisting of a raised ring surround-
ing a central lumen (Elkabetz et al., 2008). These rosette
structures were isolated and grown as neurospheres for
2 days, after which they were dissociated and plated,
yielding an adherent monolayer. No obvious differences
were observed between normal and MPS VII iPSCs during
the differentiation procedure at any point, and bothrs
Figure 2. Differentiation of NSCs from MPS VII and Normal iPSCs
Control and MPS VII iPSCs were removed from their MEF feeder layer and grown in suspension culture with FBS for 5 days to induce embryoid
body formation. The cell clusters were plated onto poly-ornithine-coated dished and grown in neural induction media. Neural tube-like
structures (white arrows) began to appear and were manually isolated at day 20 and then cultured as a suspension in neurosphere media for
2 days. Neurospheres were trypsinized and plated onto poly-ornithine/laminin-coated dishes. Trypsinized cells were passaged as nestin-
positive NSCs indefinitely.
Scale bars represent 500 mm.yielded a relatively homogenous population of putative
NSCs (Figure 2).
Characterization of MPS VII iPSC-NSCs
The majority of the iPSC-NSCs (89.9% ± 2.9%) retained
expression of the NSC marker nestin (Figures 3A and 3B).
The rate of spontaneous differentiation intoMAP2-positive
neurons (9.5% ± 0.8%) and glial fibrillary acidic protein
(GFAP)-positive astrocytes (0.4% ± 0.6%) was low (Figures
3A and 3B). Importantly, no cells expressed the pluripo-
tency marker Tra-1-60 or the reprogramming factor OCT4
(Figures 3A and 3B). The generation and culture of iPSCs
from frozen MPS VII fibroblasts and the subsequent differ-
entiation and propagation of iPSC-NSCs did not introduce
any gross chromosomal abnormalities, as shown by a
normal 46,XX karyotype (Figure 3C). To test the differenti-
ation capacity of these cells, we grew them in terminal dif-
ferentiation medium without growth factors for 1 month.
Differentiating conditions yielded neurons and astrocytes
(Figure 3D), as measured by MAP2 (86.4% ± 1.6%) and
GFAP (13.9% ± 8.2%) expression, respectively (Figure 3E).
The majority of cells (74.8% ± 5.2%) were positive for the
inhibitory neurotransmitter GABA, while there was no
evidence of tyrosine hydroxylase-positive dopaminergic
neurons (Figures 3D and 3E).
Engraftment Potential of GFP-Labeled MPS VII
iPSC-NSCs
In order to monitor the in vivo fate of iPSC-NSCs, we first
attempted to label cells with GFP using lentiviral vectorsStemwith a tropism for multiple neural cell types in vitro and
in vivo (Watson et al., 2002). Survival of MPS VII iPSC-
NSCs was very low following application of these vectors
despite attempts using multiple MOIs, pseudotypes, and
transduction conditions. To avoid this apparent toxicity,
we used a PiggyBac transposon-based approach instead.
The PiggyBac vector expressed aGFP gene and a puromycin
resistance gene. The PiggyBac plasmid was electroporated
along with a nonintegrating transposase expression
plasmid into MPS VII iPSC-NSCs. Two days after electropo-
ration, GFP expressionwas visible inmany transfected cells
(Figure 4A). Following a week of puromycin treatment,
nearly all cells were GFP positive (Figure 4B) and retained
nestin expression (Figure 4C).
To assess the engraftment potential of MPS VII iPSC-
NSCs, we intraventricularly injected GFP-labeled cells
into neonatal mice, which provide a more hospitable
environment for engraftment relative to the adult brain
(Snyder et al., 1995). Over 100 NOD-SCID neonates
were injected with iPSC-NSCs between passages 15 and
25 with no evidence of deleterious effects. By 1-month
post-transplant, cells had engrafted along the rostrocau-
dal axis of the brain and were primarily found in peri-
ventricular regions and white matter tracts (Figure 4E).
GFP-labeled MPS VII iPSC-NSCs were also transplanted
into NOD/SCID/MPS VII neonates. At 4-weeks post-
transplant, the distribution of engrafted cells was similar
to the distribution in non-MPS VII NOD/SCID litter-
mates, with cells found predominantly in and around
ventricles and white matter (Figure S2). Thus, the diseaseCell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authors 837
Figure 3. Characterization and Terminal
Differentiation of MPS VII iPSC-NSCs
(A and B) MPS VII NSC cultures expressed
nestin (89.9% ± 1.5%) and showed low
levels of spontaneous differentiation
toward neurons (MAP2, 9.5% ± 0.4%) and
astrocytes (GFAP, 0.4% ± 0.3%). No cells
expressed the reprogramming factor OCT4 or
the pluripotency marker Tra-1-60.
(C) MPS VII iPSC-NSCs had a normal 46,XX
karyotype.
(D and E) NSCs were subjected to terminal
differentiation by the removal of growth
factors and the addition of cAMP for
1 month. MAP2-positive neurons comprised
86.4% ± 0.8% of all differentiated cells.
The majority of those cells (74.8% ± 2.6%)
were GABA-positive, and none of the cells
stained positive for the dominergic marker
tyrosine hydroxylase (TH). GFAP-positive
astrocytes comprised 13.9% ± 4.1% of all
differentiated cells.
Data are represented as the mean ± SEM,
n = 4 independent cultures. Scale bars
represent 200 mm.did not alter the engraftment properties of the donor
cells.
Regardless of location, the engrafted cells expressed nes-
tin and had an immature morphology (Figure 4E, lower).
The iPSC-NSCs survived for at least 4 months (Figure 5),
with the donor cells predominantly located in the white
matter. Engrafted iPSC-NSCs remained in an immature
stage even after 4 months in vivo, as indicated by hu-
man-specific nestin immunostaining (Figure 5B). Despite
their immature phenotype, transplanted iPSC-NSCs
quickly exited the cell cycle. At 1-week post-transplant,
only a few cells expressed the cell proliferation marker
Ki67, and no Ki67-positive cells were seen at 4- or 16-weeks
post-transplant (Figure S1).
Therapeutic Potential of Corrected MPS VII iPSC-NSCs
The MPS VII iPSC-NSCs were genetically corrected and
introduced into an adult MPS VII host in order to evaluate
their therapeutic potential. The iPSC-NSCs were electropo-838 Stem Cell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authorated with a PiggyBac vector expressing the GUSB cDNA
driven by the CAG promoter. A separate culture of the
same passage of NSCs was prepared as a negative control
by electroporating them with a mock-correction vector
containing theGUSB cDNA in the reverse orientation. After
puromycin selection, the mock-corrected MPS VII iPSC-
NSCs had negligible GUSB activity (1.3 ± 1.3 nmol
4-MU/mg protein/hr) while the corrected cells showed
strong GUSB activity (116.8 ± 2.7 nmol 4-MU/mg pro-
tein/hr, p < 0.01), comparable to an iPSC-NSC line derived
from a healthy control (112.3 ± 3.1 nmol 4-MU/mg
protein/hr, p > 0.05) (Figure 6A).
MPS VII is a progressive disease with extensive pathology
present by 2 months of age (Levy et al., 1996; Snyder et al.,
1995). Therefore, 2-month-old NOD/SCID/MPS VII mice
were injected bilaterally into the striatum with 50,000 cor-
rected MPS VII iPSC-NSCs in one hemisphere and 50,000
mock-corrected cells in the contralateral hemisphere. Ani-
mals were sacrificed 1month later. Engrafted cells survived,rs
Figure 4. GFP Labeling and Distribution of Engrafted MPS VII iPSC-NSCs
(A) A PiggyBac transposon-based plasmid encoding GFP and a puromycin resistance gene was electroporated into MPS VII iPSC-NSCs.
(B) Puromycin was applied for 7 days in order to select for NSCs that had been stably transduced.
(C) MPS VII iPSC-NSCs retained their nestin expression and growth capacity after electroporation and puromycin selection.
(D) 100,000 GFP-labeled iPSC-NSCs were transplanted into the lateral ventricles of neonatal NOD/SCID mice.
(E) At 1-month post-transplant, cells were found along the rostral-caudal axis of the brain, often adjacent to ventricles and within white
matter tracts. The areas within the white boxes are enlarged in the bottom, showing the morphology of engrafted iPSC-NSCs.
Scale bars represent 200 mm (A–C), 500 mm (E, upper panels), and 30 mm (E, lower panels). See also Figures S1 and S2.remained nestin positive, and did not migrate away from
the injection site. GUSB enzymatic activity, detected by a
histochemical reaction (Snyder et al., 1995), was limited
to the injection site of the hemisphere receiving corrected
cells (Figure 6B).
To test whether the lack of differentiation and migration
was unique to our MPS VII line or to the diseased environ-
ment, we transplanted iPSC-NSCs derived from a healthy
human control, as well as MPS VII iPSC-NSCs, into NOD/
SCID (non-MPS VII) adult mice. At 1-month post-trans-
plant, engrafted cells from both lines remained at the injec-
tion site and stained positive for human-specific nestin
(Figure S3). This demonstrates that iPSC-NSCs from a
normal or a diseased source had the same properties
when transplanted into adult brain parenchyma.
To determine whether corrected or mock-corrected MPS
VII iPSC-NSCs affected neuropathology in MPS VII mice,
we used changes in activated microglia as a marker of
neuropathology. Neuroinflammation is a common findingStemin neurodegenerative diseases, and microarray analysis of
the MPS VII brain has shown that CD68, the major marker
of microglial activation, is transcribed at very high levels
(Parente et al., 2012). We confirmed via immunostaining
that CD68 was highly upregulated in NOD/SCID/MPS VII
animals early in the disease process, preceding the appear-
ance of other commonly used markers of neuropathology
(Figure S4). CD68-positive microglia were uniformly
distributed throughout the MPS VII brain by 3 months of
age (Figure 7).
One month following adult transplantation, there was
a striking reduction in CD68 immunoreactivity surround-
ing the corrected MPS VII iPSC-NSC grafts, but not
the mock-corrected grafts (Figures 7A and 7B). The density
of CD68-positive cells was quantified in a 0.5-mm2 region
of interest (ROI) surrounding each injection tract
(Figure 7C). There was a significant difference between
the region surrounding corrected grafts (49.2 ± 9.9 cells/
mm2) versus the region surrounding mock-corrected graftsCell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authors 839
Figure 5. MPS VII iPSC-NSCs Survive and Retain Nestin Expression 4 Months following Intraventricular Injection
The presence of engrafted iPSC-NSCs was revealed by immunostaining 4 months after neonatal transplantation. The highest concentra-
tions were found in and along white-matter tracts.
(A) Black boxes over Nissl-stained coronal sections show the locations of engrafted MPS VII iPSC-NSCs seen below. The location relative to
bregma (in mm) is shown above each section.
(B) Engrafted MPS VII iPSC-NSCs remained nestin positive even after 4 months in vivo.
The scale bar represents 200 mm. cc, corpus callosum; vhc, ventral hippocampal commissure; opt, optic chiasm. Nissl-stained sections are
from the Allen Mouse Brain Atlas (Allen Institute for Brain Science).(145.2 ± 13.2 cells/mm2, p < 0.0001) (Figure 7C). There was
not a significant difference between the region surround-
ing mock-corrected grafts and a comparable region of
untreated MPS VII striatum (166.1 ± 13.4 cells/mm2, p >
0.05). Immunostaining for CD68 and the pan-microglial
marker showed that the microglia in untreated MPS VII
mice as well as the microglia surrounding mock-corrected
iPSC-NSCs had a distended, amoeboid-type morphology
(Figure 7D). In contrast, the region surrounding corrected
iPSC-NSCs contained smaller, ramified-type microglia,
which closely resembled the microglia in normal control
brains (Figure 7D). As a control for the effect of localized
GUSB overexpression on CD68-positive microglia in the
absence of transplanted iPSC-NSCs, we injected adult
MPS VII mice with an AAV-GUSB vector (Passini et al.,
2003). At 1-month post-injection, there was localized
clearing of CD68-positive microglia around the injection
site (Figure S5), similar to that seen after corrected MPS
VII iPSC-NSC transplantation.DISCUSSION
Here we demonstrate the feasibility of ex vivo gene therapy
for the treatment of neuropathology accompanying meta-
bolic disease using patient-derived somatic cells from a
readily accessible source (e.g., skin biopsy). By reprogram-
ming patient fibroblasts into pluripotent stem cells and
subsequently generating genetically corrected tissue-spe-840 Stem Cell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authocific stem cells, we evaluated a therapeutic strategy that
can be applied tomany genetic diseases affecting the brain.
We show, via xenotransplantation into a mouse homolog
of the human disease, that such a strategy can reverse path-
ologic lesions surrounding the engrafted cells.
The success of NSC-based therapy will depend on proto-
cols that yieldwell-characterized and expandable lines suit-
able for transplantation. We chose an NSC differentiation
protocol for its ability to generate a self-renewing popula-
tion of relatively homogenous NSCs from ESC and iPSC
lines (Falk et al., 2012; Koch et al., 2009). The in vitro char-
acteristics of MPS VII iPSC-NSCs generated here were
consistent with reports utilizing similar ESC-based proto-
cols in regards to the immunophenotype and ability to
generate predominately GABAergic neurons upon with-
drawal of growth factors (Koch et al., 2009).
We found that GUSB deficiency did not compromise the
ability of human MPS VII iPSCs to generate embryoid
bodies or differentiate toward neural lineages, in contrast
to a previous report on a mouse MPS VII iPSC line (Meng
et al., 2010). Disease-related phenotypes have been re-
ported, in vitro, in iPSCs derived from patients with other
LSDs, such as Niemann-Pick type C or MPS IIIB (Bergamin
et al., 2013; Lemonnier et al., 2011), and in primary canine
MPS VII NSCs (Walton and Wolfe, 2007). However, there
was no evidence in our study that the MPS VII iPSC-NSCs
or their progeny had a disease-related phenotypic differ-
ence in vitro. The GUSB deficiency also did not impair
engraftment as we observed no apparent differences inrs
Figure 6. Genetic Correction of MPS VII iPSC-NSCs and Adult Transplantation
iPSC-NSCs were electroporated with a PiggyBac plasmid containing GUSB cDNA or a mock-correction vector containing GUSB cDNA in the
reverse orientation.
(A) Following puromycin selection, GUSB activity in corrected and mock-corrected MPS VII iPSC-NSCs was compared with enzyme activity
in NSCs derived from control iPSCs (mean ± SEM, n = 3 independent cultures).
(B) 50,000 cells were injected bilaterally into the striatum of 2-month-old NOD/SCID/MPS VII mice. One hemisphere received corrected
MPS VII iPSC-NSCs, and the other hemisphere received mock-corrected MPS VII iPSC-NSCs. At 1 month following transplantation, enzyme
activity was present at the injection tract in the hemisphere receiving corrected cells, but not in the hemisphere receiving mock-corrected
cells.
n = 4 mice. The scale bar represents 0.25 mm. See also Figure S3.numbers or distribution of donor NSCs between geneti-
cally corrected and mock-corrected MPS VII iPSC-NSCs
after transplantation into MPS VII mice.
Transplantation of iPSC-NSCs within the neonatal brain
yielded stable engraftment across the neuroaxis for at least
4 months, but only within and adjacent to white matter
tracts. Although the precise mechanisms are unclear,
NSCs from various sources display a tropism for white mat-
ter in both normal and pathological contexts (Carney and
Shah, 2011; Gupta et al., 2012; Maciaczyk et al., 2009;
Tabar et al., 2005). The affinity for white-matter tracts
may be useful for treating leukodystrophies or as a pathway
for NSC dissemination. The limited migration of trans-
planted NSCs within gray matter may be a barrier to
widespread delivery for some diseases with global CNS
pathology; however, axonal transport can facilitate wider
distribution of lysosomal proteins within this group of dis-
eases (Passini et al., 2002).
We transplanted iPSC-NSCs into neonatal mice in order
to evaluate their behavior in a more appropriate develop-
mental context. Many cues required for the survival and
migration of NSCs are present in neonates, but not in
healthy adults (Guzman et al., 2007). We found that
iPSC-NSCs engraft widely, but sparsely, which is consistent
with neonatal transplants of primary mouse NSCs (Chau-
bey and Wolfe, 2013). Following transplantation directly
into gray matter (adult striatum), the iPSC-NSCs remain
localized to the injection tract. As a consequence, micro-
glial pathology was corrected in a zone surrounding the
graft, corresponding to the distribution of enzyme in threeStemdimensions in the brain parenchyma (Taylor and Wolfe,
1997). Thus, substantial improvements to increase the
distribution of donor cells within the brain will be
needed to deliver the therapeutic enzyme to more areas
of the brain to advance clinically relevant NSC therapy
further for LSDs.
The engrafted iPSC-NSCs showed very little evidence
of differentiation, even 4-months post-transplant. The
absence of mature neurons and glia following neonatal
and adult transplantation stands in contrast to the profi-
ciency with which iPSC-NSCs are able to undergo terminal
differentiation in vitro. This result underscores the need for
a better understanding of the factors governing NSC differ-
entiation. However, for use in correcting most LSDs, the
differentiation status is not critical, provided that engrafted
cells do not cause deleterious effects in the brain. Undiffer-
entiated cellsmay in fact be advantageous, as inappropriate
neurotransmitter release from mature engrafted neurons
can be harmful in some settings. One example of this is
the graft-induced dyskinesias resulting from cell replace-
ment therapy for Parkinson’s disease (Lane et al., 2010).
Gene- and cell-based therapies that successfully deliver
lysosomal enzymes in the brain reduce pathology in
many animal models of LSD (Simonato et al., 2013). To
test whether genetically corrected patient iPSC-NSCs could
deliver corrective levels of GUSB, we evaluated pathology
in the striatum surrounding engrafted cells in adult MPS
VII brains. We assayed disease-associated neuroinflamma-
tion as a biomarker, using CD68-positive activated micro-
glia. A microglial contribution to MPS VII pathology wasCell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authors 841
Figure 7. Correction of Microglial Pathology following iPSC-NSC Transplantation
Corrected and mock-corrected iPSC-NSCs (50,000 cells/condition) were injected intrastriatally into the right and left hemisphere,
respectively, of adult NOD/SCID/MPS VII mice.
(A) Schematic of a representative coronal section showing engrafted MPS VII iPS-NSCs and CD68-positive microglia at 1-month
post-transplantation.
(B) Immunofluorescent images of nestin-positive iPS-NSCs at the site of injection. The region surrounding the corrected MPS VII iPSC-NSCs
contained significantly fewer activated microglia than in the region surrounding mock-corrected MPS VII iPSC-NSCs or in a comparable
region of untreated MPS VII striatum.
(C) CD68-positive microglia with an area greater than 20 pixels were quantified.
(D) Confocal images of IBA1 and CD68 immunoreactivity in resident microglia. The brains of MPS VII mice showed marked microglial
activation, as evident by upregulated CD68 expression and amoeboid morphology. Microglia adjacent to corrected, but not mock-
corrected, MPS VII iPSC-NSCs exhibited a ramified morphology and low CD68 expression typical of the quiescent microglia found in
normal mice.
Mean ± SEM, n = 3 sections/mouse, n = 4 mice. Scale bars represent 200 mm in (B) and 30 mm in (D). See also Figures S4 and S5.previously shown via microarray analysis of normal and
diseased brains (Parente et al., 2012). Microglia involve-
ment has been well documented in some, but not all, stor-
age diseases, including MPS IIIb and Sandhoff disease
(Ohmi et al., 2003; Wada et al., 2000), and activated
CD68-positive microglia have been used as a biomarker842 Stem Cell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authofor correction of pathology (Lee et al., 2007). We show
here that microglia are a significant and early component
of MPS VII neuropathology. The CD68-positive microglia
are particularly useful as a quantifiable biomarker of MPS
VII neuropathology because of their distended size, spher-
ical morphology, and uniform distribution.rs
We observed no differences in the ability to establish
grafts between corrected and mock-corrected MPS VII
iPSC-NSCs. The diseased area surrounding the mock-
corrected grafts was essentially the same as untreated
MPS VII brains in the same region, and the activatedmicro-
glia had a distended ameboid appearance. In contrast, the
area surrounding the grafts of the corrected MPS VII iPSC-
NSCs had significantly fewer CD68-positive cells, and the
remaining microglia were reduced in size and adopted a
more ramified-type morphology consistent with the state
of resting microglia seen in normal animals.
The lack of benefit derived frommock-corrected grafts in-
dicates that GUSB alone was responsible for correcting the
neuropathology, rather than anti-inflammatory or other
factors expressed by the iPSC-NSCs themselves. The obser-
vation that GUSB overexpression from an AAV vector simi-
larly reduces CD68-positive microglia corroborates the
conclusion that GUSB activity is solely responsible for the
correction of neuropathology.
The spatially constrained nature of correction following
cell transplantation indicates the need for new differentia-
tion protocols or other strategies capable of increasing NSC
migration within the brain parenchyma. Overall, our
results suggest that a comprehensive strategy involving
somatic reprogramming and gene therapy could benefit
patients with neuropathology from storage diseases
affecting the brain.EXPERIMENTAL PROCEDURES
Generation of MPS VII iPSCs
Frozen fibroblasts were obtained from a 3-month-old female pa-
tient (GM02784; Coriell Institute for Medical Research) with no
detectable b-glucuronidase activity. Fibroblasts were maintained
in DMEM containing 15% FBS. Reprogramming was performed
as previously described with some modifications (Park et al.,
2008). Retroviral vectors expressing OCT4, SOX2, KLF4, and
c-MYC were produced in 293t cells using the pMXs backbone
(courtesy of Dr. Shinya Yamanaka, Addgene plasmids 13366,
13367, 13375, and 17219) and pseudotyped with VSV-G (Takaha-
shi and Yamanaka, 2006). MPS VII fibroblasts were transduced
with the reprogramming vectors and after 5 days were split onto
mitomycin-C inactivated MEFs. The cells were maintained in
iPSC media containing ROCK inhibitor Y-27632 (10 mM; Sigma)
until colonies were ready to be picked. Putative iPSC colonies
weremanually picked and transferred to freshMEFs. Subsequently,
iPSC cultures were passaged eithermanually or enzymatically with
dispase (GIBCO). Control iPSCs were obtained from the ESC/iPSC
core of theChildren’s Hospital of Philadelphia and generated using
theCre-excisable STEMCAA lentiviral vector (Sommer et al., 2010).Teratoma Formation
MPS VII iPSCs (1 3 106) were resuspended in 140 ml DMEM/F12
and mixed with 60 ml matrigel (BD Biosciences). The cell suspen-Stemsion was injected subcutaneously in NOD/SCID mice (Jackson
Labs). Teratomas were removed 6 weeks later and either frozen
for immunostaining or embedded in paraffin for H&E staining.
Differentiation and Culture of NSCs
MPS VII and control iPSCs were differentiated based on a protocol
for generating long-term self-renewing NSCs from ESCs (Koch
et al., 2009). Briefly, iPSC colonies were removed from the MEF
feeder layer, and 20% FBS was added in order to generate embryoid
bodies. At day 5, the embryoid bodies were attached to poly-
ornithine-coated (Sigma) dishes and switched to a minimal neural
induction media containing insulin, transferrin, selenium, and
fibronectin (Sigma) until neural tube-like structures appear. At
day 20, these tube-like structures were manually removed from
the surrounding cell mass using a dissecting microscope and
transferred to a suspension culture containing N-2 supplement
(1:100; GIBCO), basic fibroblast growth factor (bFGF) (10 ng/ml;
GIBCO), and EGF (10 ng/ml; Sigma). Cells were trypsinized at
day 23 and plated on poly-ornithine/laminin-coated (BD Biosci-
ences) plates in NSC media containing bFGF (10 ng/ml), EGF
(10 ng/ml), insulin (20 mg/ml; GIBCO), N-2 (1:100), and B-27
(1:1,000; GIBCO). iPSC-NSCs were passaged 1:2 every 3 to 4 days
by trypsinization.
Characterization of iPSC-NSCs
G-banded karyotyping of iPSC-NSCs (p9) was performed by Cell
Line Genetics. Terminal in vitro differentiation was carried out in
Neurobasal:DMEM/F12 (GIBCO) containing N-2 (1:100), B-27
(1:100), and cyclic AMP (300 ng/ml; Sigma) for 1 month. Quanti-
fication of the percentage of undifferentiated and terminally differ-
entiated iPSC-NSCs expressing cell-type specific markers was
performed by manual counting of immunofluorescently labeled
slides. Percentages are represented as means ± SEM (n = 4).
Gene Transfer in MPS VII iPSC-NSCs
GFP labeling of iPSC-NSCs was achieved using a PiggyBac expres-
sion vector containing a puromycin resistance gene (PB-513B-1;
Systems Biosciences). The CMV promoter sequence was replaced
with the CAG promoter sequence using SpeI and EcoRI. GUSB
was cloned into the PiggyBac plasmid using SmaI sites flanking
the GUSB cDNA and a SwaI site within the multiple cloning site
of the PiggyBac plasmid. Blunt-end ligation produced a correction
vector as well a mock-correction vector containing GUSB in the
reverse orientation. For transfection of iPSC-NSCs, we used the
Lonza Kit for Mouse Neural Stem Cells according to the manufac-
turer instructions; 43 106 cells were electroporatedwith 3 mg of the
GUSB expression vector or GFP control + 1 mg of the transposase
expression plasmid (PB200PA-1; Systems Biosciences) using the
Lonza Nucleofector set to program A-33. After allowing the cells
a few days to recover, transfected cells were selected with
0.5 mg/ml puromycin for 1 week.
Neonatal NSC Transplantation
Neonatal NOD/SCID mice were cryoanesthetized prior to trans-
plantation. iPSC-NSCs were trypsinized and resuspended in PBS
at 50,000 cells per ml; 2 ml of the cell suspension was injected
into each lateral ventricle using a pulled glass micropipette. AllCell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authors 843
procedures were approved by the Institutional Care and Use Com-
mittee at the Children’s Hospital of Philadelphia.
Adult NSC Transplantation
Prior to injection, 8-week-old NOD/SCID or NOD/SCID/MPS VII
mice (breeding stock was a kind gift of Drs. M. Sands and J. Nolta)
were anesthetized with isofluorane and secured in a sterotaxic
frame (Kopf). Burr holes were drilled into the skull, and 50,000 cor-
rected or mock-corrected cells in 1 ml PBS were infused at a rate of
0.5 ml/min. The striatal coordinates were 0.50 mm caudal to
bregma, 1.5 mm left or right of midline, and 3.0 mm ventral to
the dural surface.
Adult AAV Injection
Prior to injection, 8-week-old C57BL/6/MPS VII mice (n = 4) were
anesthetized with isofluorane and secured in a sterotaxic frame
(Kopf). Burr holes were drilled into the skull, and AAV2/1 vector
in 1 ml of PBS was infused at a rate of 0.5 ml/min. One hemisphere
was injected with AAV2/1-GFP, and the contralateral hemisphere
was injected with a 1:1 mixture of AAV2/1-GFP and AAV2/1-
GUSB (total of 1 3 1011 vector genomes). Packaging, purification,
and titering were performed by The University of Pennsylvania
Vector Core as previously described (Passini et al., 2003). The coor-
dinates used for injectionwere 0.50mm rostral to bregma, 1.5mm
left or right of midline, and 3.0 mm ventral to the dural surface.
Immunostaining
Brains were embedded in 2% agarose prior to vibratome sectioning
and immunostaining; 60 mm coronal sections were stored in PBS +
0.1%Na azide at 4C until ready for use. Brains were cryoprotected
with 30% sucrose prior to embedding in OCT (Tissue-Tek); 20-mm-
thick frozen sections were cut using a cryostat (Leica). Vibratome
and frozen sections were postfixed in 4% paraformaldehyde and
permeabilized in 0.3% Triton X-100. After blocking in 4% goat
serum, the sections were incubated in primary antibody contain-
ing 1% serum for 1 hr at room temperature. Antibodies used and
their concentrations are listed in Table S1. Images were acquired
using an epifluorescence microscope (DM6000 B; Leica) or a
confocal-scanning laser microscope (FluoView1000; Olympus).
Image Analysis and Statistics
To visualize the distribution of CD68-positivemicroglia inMPS VII
mice following adult iPSC-NSC engraftment, we combined a
montage of immunofluorescent images using the photomerge
tool in Photoshop CS6 (Adobe). ImagePro Plus 3.0 (Media Cyber-
netics) was used to identify and dilate all objects with an area
greater than 20 pixels. CD68-positive microglia were quantified
within 0.25 mm of engrafted iPSC-NSCs. The density of microglia
adjacent to corrected and mock-corrected cells was compared by
two-tailed t test using Prism 5.0 (Graphpad). Microglia with a
CD68-positive area greater than 20 pixels were counted. Frozen
sections (20 mm) were quantified for each condition, and data are
represented as means ± SEM (n = 7).
b-Glucuronidase Assays
Napthol-AS-BI-b-D-glucuronide was used to determine the pres-
ence of GUSB activity in 20-mm-thick frozen sections as previously844 Stem Cell Reports j Vol. 4 j 835–846 j May 12, 2015 j ª2015 The Authodescribed (Snyder et al., 1995). For quantitation of b-glucuronidase
activity in MPS VII and control NSCs, the fluorescence of hydro-
lyzed 4-methylumbelliferyl-b-D-glucuronide was measured as pre-
viously described (Cervera, 2005). Three independent cultures
were quantified, and data are represented as means ± SEM.SUPPLEMENTAL INFORMATION
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